PMID- 12204805
OWN - NLM
STAT- MEDLINE
DCOM- 20030206
LR  - 20190718
IS  - 0021-9150 (Print)
IS  - 0021-9150 (Linking)
VI  - 164
IP  - 2
DP  - 2002 Oct
TI  - Coronary artery calcification is related to functional polymorphism of matrix 
      metalloproteinase 3: the Helsinki Sudden Death Study.
PG  - 329-35
AB  - Matrix metalloproteinase 3 (MMP3) is expressed in human coronary atherosclerotic 
      lesions and is known to be involved in degradation of the plaque and to be 
      co-localized with calcium and fibrin deposits in advanced lesions, indicating a 
      possible role of MMP3 in arterial calcification. The MMP3 gene promoter 
      polymorphism leads to low promoter activity 6A6A, intermediate promoter activity 
      5A6A and high promoter activity 5A5A genotypes. To determine whether these 
      genotypes predict the extent of atherosclerosis we investigated their association 
      with different types of coronary lesions in an autopsy series of 300 middle-aged 
      white Finnish men (aged 35-69 years) from the Helsinki Sudden Death Study (HSDS). 
      Areas of the coronary wall covered with different atherosclerotic lesions were 
      measured and MMP3 genotypes were determined by PCR and minisequencing. In men 
      >/=53 years the mean area of calcified lesion in the most severely affected 
      coronary artery was significantly associated with the MMP3 genotype (P=0.029). 
      Subjects with high promoter activity genotypes had on average larger calcified 
      lesion areas than those with the low-activity genotype. The MMP3 genotype 
      (P=0.025) persisted as an independent predictor of mean calcified lesion area 
      after stepwise adjustment for age, BMI, hypertension, diabetes, number of 
      affected vessels and smoking. These data provide evidence that the proposed 
      effect of MMP3 in the process of atherogenesis may be modified by the MMP3 
      genotype.
FAU - Pollanen, Perttu J
AU  - Pollanen PJ
AD  - Laboratory of Atherosclerosis Genetics, Department of Clinical Chemistry, Centre 
      for Laboratory Medicine, Tampere University Hospital, FinnMedi 2 3rd fl., PO Box 
      2000, FIN-33521, Tampere, Finland.
FAU - Lehtimaki, Terho
AU  - Lehtimaki T
FAU - Ilveskoski, Erkki
AU  - Ilveskoski E
FAU - Mikkelsson, Jussi
AU  - Mikkelsson J
FAU - Kajander, Olli A
AU  - Kajander OA
FAU - Laippala, Pekka
AU  - Laippala P
FAU - Perola, Markus
AU  - Perola M
FAU - Goebeler, Sirkka
AU  - Goebeler S
FAU - Penttila, Antti
AU  - Penttila A
FAU - Mattila, Kari M
AU  - Mattila KM
FAU - Syrjakoski, Kirsi
AU  - Syrjakoski K
FAU - Koivula, Timo
AU  - Koivula T
FAU - Nikkari, Seppo T
AU  - Nikkari ST
FAU - Karhunen, Pekka J
AU  - Karhunen PJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alleles
MH  - Analysis of Variance
MH  - Autopsy
MH  - Base Sequence
MH  - Calcinosis/*pathology
MH  - Cohort Studies
MH  - Coronary Disease/*genetics/*mortality/pathology
MH  - Coronary Vessels/*pathology
MH  - Death, Sudden, Cardiac/*pathology
MH  - Finland
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/*genetics
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Polymerase Chain Reaction
MH  - *Polymorphism, Genetic
MH  - Probability
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
EDAT- 2002/09/03 10:00
MHDA- 2003/02/07 04:00
CRDT- 2002/09/03 10:00
PHST- 2002/09/03 10:00 [pubmed]
PHST- 2003/02/07 04:00 [medline]
PHST- 2002/09/03 10:00 [entrez]
AID - S0021-9150(02)00107-7 [pii]
AID - 10.1016/s0021-9150(02)00107-7 [doi]
PST - ppublish
SO  - Atherosclerosis. 2002 Oct;164(2):329-35. doi: 10.1016/s0021-9150(02)00107-7.